Tags

Type your tag names separated by a space and hit enter

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428].
BMC Ophthalmol. 2005 Apr 05; 5:6.BO

Abstract

BACKGROUND

Reduced choroidal perfusion is hypothesized to play a role in the pathogenesis of normal tension glaucoma. Thus the impact of antiglaucomatous eye drops on ocular perfusion has been the focus of recent research and the subject of intensive investigations. The present study investigates whether topically applied latanoprost or bimatoprost influence ocular perfusion in patients with normal tension glaucoma and compares these effects with that changes detected after the treatment with dorzolamide.

METHODS

Ocular hemodynamics were assessed by color Doppler imaging (CDI) shortly before and after a one-month treatment with either latanoprost, bimatoprost or dorzolamide. Primary end-points of the study were peak systolic and end-diastolic blood flow velocities in the short posterior ciliary artery (SPCA) under the new therapy. Intraocular pressure (IOP) and additional perfusion parameters in the SPCA and other retrobulbar vessels were tracked as observational parameters. n = 42 patients with normal tension glaucoma were enrolled in the study.

RESULTS

Systolic and diastolic blood flow velocities in the SPCA showed no significant alteration after the treatment with latanoprost or bimatoprost. Dorzolamide lead to increase of peak systolic velocity. IOP was reduced by all three agents in a range reported in the literature.

CONCLUSION

Topically applied latanoprost and bimatoprost act in a hemodynamically neutral manner and have the capability to lower IOP even in patients with normal tension glaucoma and low initial IOP level. Dorzolamide accelerates blood flow in systole. None of the tested compounds has a negative impact on hemodynamics in the short posterior ciliary arteries.

Authors+Show Affiliations

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Augenheilkunde, Martinistr, 52, D-20246 Hamburg, Germany. zeitz@uke.uni-hamburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15811188

Citation

Zeitz, Oliver, et al. "Effects of Glaucoma Drugs On Ocular Hemodynamics in Normal Tension Glaucoma: a Randomized Trial Comparing Bimatoprost and Latanoprost With Dorzolamide [ISRCTN18873428]." BMC Ophthalmology, vol. 5, 2005, p. 6.
Zeitz O, Matthiessen ET, Reuss J, et al. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmol. 2005;5:6.
Zeitz, O., Matthiessen, E. T., Reuss, J., Wiermann, A., Wagenfeld, L., Galambos, P., Richard, G., & Klemm, M. (2005). Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmology, 5, 6.
Zeitz O, et al. Effects of Glaucoma Drugs On Ocular Hemodynamics in Normal Tension Glaucoma: a Randomized Trial Comparing Bimatoprost and Latanoprost With Dorzolamide [ISRCTN18873428]. BMC Ophthalmol. 2005 Apr 5;5:6. PubMed PMID: 15811188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. AU - Zeitz,Oliver, AU - Matthiessen,Eike T, AU - Reuss,Juliane, AU - Wiermann,Anne, AU - Wagenfeld,Lars, AU - Galambos,Peter, AU - Richard,Gisbert, AU - Klemm,Maren, Y1 - 2005/04/05/ PY - 2004/10/24/received PY - 2005/04/05/accepted PY - 2005/4/7/pubmed PY - 2006/2/4/medline PY - 2005/4/7/entrez SP - 6 EP - 6 JF - BMC ophthalmology JO - BMC Ophthalmol VL - 5 N2 - BACKGROUND: Reduced choroidal perfusion is hypothesized to play a role in the pathogenesis of normal tension glaucoma. Thus the impact of antiglaucomatous eye drops on ocular perfusion has been the focus of recent research and the subject of intensive investigations. The present study investigates whether topically applied latanoprost or bimatoprost influence ocular perfusion in patients with normal tension glaucoma and compares these effects with that changes detected after the treatment with dorzolamide. METHODS: Ocular hemodynamics were assessed by color Doppler imaging (CDI) shortly before and after a one-month treatment with either latanoprost, bimatoprost or dorzolamide. Primary end-points of the study were peak systolic and end-diastolic blood flow velocities in the short posterior ciliary artery (SPCA) under the new therapy. Intraocular pressure (IOP) and additional perfusion parameters in the SPCA and other retrobulbar vessels were tracked as observational parameters. n = 42 patients with normal tension glaucoma were enrolled in the study. RESULTS: Systolic and diastolic blood flow velocities in the SPCA showed no significant alteration after the treatment with latanoprost or bimatoprost. Dorzolamide lead to increase of peak systolic velocity. IOP was reduced by all three agents in a range reported in the literature. CONCLUSION: Topically applied latanoprost and bimatoprost act in a hemodynamically neutral manner and have the capability to lower IOP even in patients with normal tension glaucoma and low initial IOP level. Dorzolamide accelerates blood flow in systole. None of the tested compounds has a negative impact on hemodynamics in the short posterior ciliary arteries. SN - 1471-2415 UR - https://www.unboundmedicine.com/medline/citation/15811188/Effects_of_glaucoma_drugs_on_ocular_hemodynamics_in_normal_tension_glaucoma:_a_randomized_trial_comparing_bimatoprost_and_latanoprost_with_dorzolamide_[ISRCTN18873428]_ L2 - https://bmcophthalmol.biomedcentral.com/articles/10.1186/1471-2415-5-6 DB - PRIME DP - Unbound Medicine ER -